Literature DB >> 27489345

Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA).

Zhe Li Salie1, Karen A Kirby2, Eleftherios Michailidis2, Bruno Marchand2, Kamalendra Singh2, Lisa C Rohan3, Eiichi N Kodama4, Hiroaki Mitsuya5, Michael A Parniak6, Stefan G Sarafianos7.   

Abstract

4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) is the most potent nucleoside analog inhibitor of HIV reverse transcriptase (RT). It retains a 3'-OH yet acts as a chain-terminating agent by diminishing translocation from the pretranslocation nucleotide-binding site (N site) to the posttranslocation primer-binding site (P site). Also, facile misincorporation of EFdA-monophosphate (MP) results in difficult-to-extend mismatched primers. To understand the high potency and unusual inhibition mechanism of EFdA, we solved RT crystal structures (resolutions from 2.4 to 2.9 Å) that include inhibition intermediates (i) before inhibitor incorporation (catalytic complex, RT/DNA/EFdA-triphosphate), (ii) after incorporation of EFdA-MP followed by dT-MP (RT/DNAEFdA-MP(P)• dT-MP(N) ), or (iii) after incorporation of two EFdA-MPs (RT/DNAEFdA-MP(P)• EFdA-MP(N) ); (iv) the latter was also solved with EFdA-MP mismatched at the N site (RT/DNAEFdA-MP(P)• EFdA-MP(*N) ). We report that the inhibition mechanism and potency of EFdA stem from interactions of its 4'-ethynyl at a previously unexploited conserved hydrophobic pocket in the polymerase active site. The high resolution of the catalytic complex structure revealed a network of ordered water molecules at the polymerase active site that stabilize enzyme interactions with nucleotide and DNA substrates. Finally, decreased translocation results from favorable interactions of primer-terminating EFdA-MP at the pretranslocation site and unfavorable posttranslocation interactions that lead to observed localized primer distortions.

Entities:  

Keywords:  EFdA; HIV-1 reverse transcriptase; NRTIs; X-ray crystallography; inhibitors

Mesh:

Substances:

Year:  2016        PMID: 27489345      PMCID: PMC4995989          DOI: 10.1073/pnas.1605223113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  Antiviral therapies: focus on hepatitis B reverse transcriptase.

Authors:  Eleftherios Michailidis; Karen A Kirby; Atsuko Hachiya; Wangdon Yoo; Sun Pyo Hong; Soo-Ok Kim; William R Folk; Stefan G Sarafianos
Journal:  Int J Biochem Cell Biol       Date:  2012-04-16       Impact factor: 5.085

2.  2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity.

Authors:  Hiroshi Ohrui
Journal:  Chem Rec       Date:  2006       Impact factor: 6.771

3.  Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs.

Authors:  Atsuko Hachiya; Aaron B Reeve; Bruno Marchand; Eleftherios Michailidis; Yee Tsuey Ong; Karen A Kirby; Maxwell D Leslie; Shinichi Oka; Eiichi N Kodama; Lisa C Rohan; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2013-06-24       Impact factor: 5.191

4.  4'-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus.

Authors:  Yuki Takamatsu; Yasuhito Tanaka; Satoru Kohgo; Shuko Murakami; Kamalendra Singh; Debananda Das; David J Venzon; Masayuki Amano; Nobuyo Higashi-Kuwata; Manabu Aoki; Nicole S Delino; Sanae Hayashi; Satoru Takahashi; Yoshikazu Sukenaga; Kazuhiro Haraguchi; Stefan G Sarafianos; Kenji Maeda; Hiroaki Mitsuya
Journal:  Hepatology       Date:  2015-08-25       Impact factor: 17.425

5.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

6.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

7.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance.

Authors:  H Huang; R Chopra; G L Verdine; S C Harrison
Journal:  Science       Date:  1998-11-27       Impact factor: 47.728

8.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

9.  Trapping HIV-1 reverse transcriptase before and after translocation on DNA.

Authors:  Stefan G Sarafianos; Arthur D Clark; Steve Tuske; Christopher J Squire; Kalyan Das; Dequan Sheng; Palanichamy Ilankumaran; Andagar R Ramesha; Heiko Kroth; Jane M Sayer; Donald M Jerina; Paul L Boyer; Stephen H Hughes; Eddy Arnold
Journal:  J Biol Chem       Date:  2003-01-28       Impact factor: 5.157

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  30 in total

1.  CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.

Authors:  Nobuyo Higashi-Kuwata; Sanae Hayashi; Debananda Das; Satoru Kohgo; Shuko Murakami; Shin-Ichiro Hattori; Shuhei Imoto; David J Venzon; Kamalendra Singh; Stefan G Sarafianos; Yasuhito Tanaka; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 2.  Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance.

Authors:  Francesc Xavier Ruiz; Eddy Arnold
Journal:  Curr Opin Struct Biol       Date:  2020-01-11       Impact factor: 6.809

3.  Antiretroviral potency of 4'-ethnyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes.

Authors:  Duncan T Njenda; Shambhu G Aralaguppe; Kamalendra Singh; Rohit Rao; Anders Sönnerborg; Stefan G Sarafianos; Ujjwal Neogi
Journal:  J Antimicrob Chemother       Date:  2018-10-01       Impact factor: 5.790

4.  The High Genetic Barrier of EFdA/MK-8591 Stems from Strong Interactions with the Active Site of Drug-Resistant HIV-1 Reverse Transcriptase.

Authors:  Yuki Takamatsu; Debananda Das; Satoru Kohgo; Hironori Hayashi; Nicole S Delino; Stefan G Sarafianos; Hiroaki Mitsuya; Kenji Maeda
Journal:  Cell Chem Biol       Date:  2018-08-30       Impact factor: 8.116

5.  MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.

Authors:  Vincent H Wu; Robert A Smith; Sara Masoum; Dana N Raugi; Selly Ba; Moussa Seydi; Jay A Grobler; Geoffrey S Gottlieb
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

6.  Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.

Authors:  Vasudevan Achuthan; Kamlendra Singh; Jeffrey J DeStefano
Journal:  Biochemistry       Date:  2016-12-27       Impact factor: 3.162

7.  Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine.

Authors:  Nicole Bertoletti; Albert H Chan; Raymond F Schinazi; Y Whitney Yin; Karen S Anderson
Journal:  Protein Sci       Date:  2019-08-06       Impact factor: 6.725

8.  An Update on Antiretroviral Therapy.

Authors:  Luis Menéndez-Arias; Samara Martín-Alonso; Estrella Frutos-Beltrán
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor.

Authors:  Martin Markowitz; Stefan G Sarafianos
Journal:  Curr Opin HIV AIDS       Date:  2018-07       Impact factor: 4.283

10.  7-Deaza-7-fluoro modification confers on 4'-cyano-nucleosides potent activity against entecavir/adefovir-resistant HBV variants and favorable safety.

Authors:  Sanae Hayashi; Nobuyo Higashi-Kuwata; Debananda Das; Kota Tomaya; Kohei Yamada; Shuko Murakami; David J Venzon; Shin-Ichiro Hattori; Masanori Isogawa; Stefan G Sarafianos; Hiroaki Mitsuya; Yasuhito Tanaka
Journal:  Antiviral Res       Date:  2020-02-18       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.